Navigation Links
CSL Biotherapies Announces FDA Marketing Approval of its Monovalent Pandemic (H1N1) 2009 Influenza A Vaccine
Date:9/16/2009

CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics licensing application for licensure of its monovalent pandemic (H1N1) 2009 influenza A vaccine for active immunization of persons age 18 years and older against influenza disease caused by the H1N1 virus.

King of Prussia, PA (PRWEB) September 16, 2009 -- CSL Biotherapies, a subsidiary of CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics licensing application for licensure of its monovalent pandemic (H1N1) 2009 influenza A vaccine for active immunization of persons age 18 years and older against influenza disease caused by the H1N1 virus.

"The FDA's licensure of our H1N1 vaccine is a significant milestone in CSL's efforts to bring an effective pandemic influenza vaccine to the U.S. and Southern hemisphere markets," said Paul Perreault, President, CSL Biotherapies. "We're pleased to have contributed important clinical trial data on this vaccine to regulatory authorities in the United States and Australia. CSL Biotherapies will continue to work closely with the U.S. government to supply pandemic H1N1 vaccine as quickly as possible in order to assist in national efforts to protect the health of Americans."

CSL Biotherapies has an initial contract worth $180 million to deliver bulk H1N1 vaccine antigen to the U.S. Health and Human Services Department (HHS), with an option for filling and packaging services out of CSL's Kankakee, Illinois and Marburg, Germany facilities. These facilities have the capability to produce influenza vaccine in thimerosal-free, prefilled, single-use syringes and in multi-dose vials containing preservative. CSL will supply bulk H1N1 antigen to the U.S. and will formulate that bulk as directed by the federal government. CSL expects to begin delivery of bulk H1N1 antigen to HHS in October, 2009.

About CSL Biotherapies:
The United States headquarters of CSL Biotherapies are located in King of Prussia, PA. Its parent company, CSL Limited, in Melbourne, Australia, has made a $60 million (U.S.D.) investment in plant and equipment to double the manufacturing capacity of the company's Melbourne facility to 40 million doses per season; it is now one of the world's largest influenza vaccine facilities for global markets. CSL Biotherapies, which shares its United States headquarters with its sister company, CSL Behring, is commercializing influenza vaccine products globally.

The CSL Group, which includes CSL Biotherapies, CSL Research & Development, CSL Bioplasma, and CSL Behring, has more than 10,000 employees and operates in 27 countries worldwide. For more information, visit us at www.cslbiotherapies-us.com, or call 1-888-435-8633.

Media Contacts:

Sheila A. Burke
Director, Public Relations & Communications
Worldwide Commercial Operations
CSL Biotherapies
610-290-7403
484-919-2618 (mobile)

Elizabeth Fisher-Au
Weber-Shandwick
212-445-8111

###

Read the full story at http://www.prweb.com/releases/H1N1_vaccine/Influenza_Vaccine/prweb2893274.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. FindFloridaLawyer.com Announces the Grand Opening of Its Online Attorney Search and Legal Resource Site
2. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
3. Cowen Announces Hiring of Don Munoz to Lead Medical Technology Practice; 5th Senior-Level Addition to Cowens Health Care Franchise in 2009
4. Metametrix Announces Availability of Phthalates & Parabens Profile to Help Identify Everyday Exposures
5. Post Acute Medical / Warm Springs Announces Long-Term Contractual Relationship With Gulf States LTAC of New Braunfels
6. ASAP Systems Announces Additional Changes to its Inventory, Warehouse, Stock Tracking, Capital and Fixed Assets Management System and Reseller Program
7. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
8. Nuvilex, Inc. Announces That Reme-Flu(TM) Will Be Available For Sale On Top-Rated Internet Website
9. Global Med Technologies(R), Inc. Announces Its First EdgeCell Cellular Therapy Software and EdgeLab/HLA Software Sale in North America
10. Accumetrics, Inc. Announces Endotech SPA as Exclusive Distributor for the VerifyNow System in Italy
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CSL Biotherapies Announces FDA Marketing Approval of its Monovalent Pandemic (H1N1) 2009 Influenza A Vaccine 
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: